

AT A GLANCE

technology

SIMPLE Antibody™ platform: structurally human, functionally comprehensive.

strategy

To mine a powerful immune system with precision technology, maximizing success in antibody drug discovery.

advantage

With technology offering superior candidate choice in lead discovery, arGEN-X selects and configures therapeutic antibodies with the desired product profile in mind.

credentials

A team of innovators with highly complementary competences and an established track record in the research, development and commercialization of monoclonal antibodies.

founded 2008

arGEN-X B.V.

Dr Molewaterplein 50
3015 GE Rotterdam
The Netherlands

arGEN-X BVBA

Technologiepark 30
9052 Zwijnaarde
Belgium

www.arGEN-X.com

COMPANY OVERVIEW

a transforming force

arGEN-X is an innovative biopharmaceutical company playing a transforming role in the human therapeutic antibody space.

*Its business is based on the **SIMPLE Antibody™** discovery engine: a rich and diverse source of unique antibody candidates with enormous therapeutic potential.*

*The **SIMPLE Antibody™** platform generates human antibody leads of unparalleled functional diversity which routinely exhibit gold standard affinities, potencies and expression levels.*

*The platform is effectively applied across all target classes, including complex cell surface receptors. The consistent recovery of unique antibody leads enables rapid development of product candidates with desirable properties. The **SIMPLE Antibody™** approach maximizes the likelihood of success in therapeutic product development.*

arGEN-X is building a portfolio of novel preclinical programs addressing multiple therapeutic areas. Its lead program is pursuing a target implicated in autoimmunity, while three further discovery programs in inflammation and oncology are underway.

*The **SIMPLE Antibody™** technology is covered by broad composition of matter and process patent claims. arGEN-X benefits both from freedom to operate and from absence of any gatekeeping restrictions on targets.*

market opportunity

Past demand for monoclonal antibody (mAb) technologies was driven by the genomics revolution and the launch of human-like mAb products aimed at reducing immunogenicity.

Current demand is greater than ever, but for different reasons: the phenomenal commercial success of mAb products (global sales exceeding \$24B in 2008, with annual growth projected at ~10-15% annually [Datamonitor]), and the relative scarcity of antibody technologies and attractive preclinical candidates available for licensing to biopharmaceuticals developers.

AT A GLANCE

management

Tim Van Hauwermeiren, MSc, eMBA
Chief Executive Officer

Prof. Hans de Haard, PhD
Chief Scientific Officer

Torsten Dreier, PhD
Chief Development Officer

Michael Saunders, PhD, MBA
Sr Director Targets & Programs

supervisory board

Peter Verhaeghe, LL.M.
Chairman - Partner, VV&G

Christina Takke, PhD
Principal, FCP

John de Koning, PhD
Partner, LSP

Philippe Guinot, MD, PhD
*Senior Partner Credit Agricole
Private Equity*

Harrold van Barlingen, PhD
*Founder and Managing Director
Thuja Capital*

Johan Cardoen, PhD
*Independent
Chairman FlandersBio,
CEO Cropdesign NV*

investors



COMPANY OVERVIEW

MABs continue to be the format of choice for safe, efficacious biological drugs. Intrinsic properties of excellent target specificity, high binding affinity, prolonged systemic circulation and in-built effector function are highly sought after.

The **SIMPLE Antibody™** approach meets the challenge of identifying such mAbs - and ensuring their mode of action translates into a therapeutic effect.

arGEN-X is committed to being the partner of choice for creation of the next generation of blockbuster antibody drugs – effectively transforming therapeutic antibody discovery.

business development strategy

arGEN-X is fulfilling its potential to meet demand for innovative mAb technologies in creating high value products.

Through discovery-driven collaborations both on novel targets and on targets intractable with other technologies, arGEN-X aims to develop preclinical programs with exciting product potential. In addition, arGEN-X intends to enhance its own therapeutic antibody programs through partnership.

For further discussion of licensing or collaboration opportunities, please contact us at business.development@arGEN-X.com